RxDoctor Payments Data

Silvio Goris, MD

Internal Medicine · Bronx, NYNPI 1982068078

Payments from drug & device makers

$1,067in general payments, 2019–2025

Across 42 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$489
  • Viiv Healthcare Company$245
  • AstraZeneca$107
  • Lilly USA, LLC$90
  • Novartis$60
  • Abbott$22
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$1,067100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK25$489
Viiv Healthcare Company2$245
AstraZeneca3$107
Lilly USA, LLC5$90
Novartis3$60
Abbott1$22
Lundbeck LLC1$20
AbbVie1$20
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,067 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$10,137
Medicare patients
23
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin128$131,942
OzempicSemaglutide48$68,264
JanuviaSitagliptin Phosphate67$58,574
TrulicityDulaglutide40$53,399
EntrestoSacubitril/Valsartan32$31,145
EliquisApixaban33$28,294
RybelsusSemaglutide21$22,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,734
LinzessLinaclotide29$16,863
JanumetSitagliptin Phos/Metformin Hcl12$14,590
Janumet XrSitagliptin Phos/Metformin Hcl15$12,267
FarxigaDapagliflozin Propanediol12$10,723
VascepaIcosapent Ethyl15$6,720
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$6,447
Atorvastatin Calcium481$5,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$14$85,43094 claims
Lilly USA, LLCTrulicity$90$53,39940 claims
NovartisEntresto$60$31,14532 claims
GSKTrelegy Ellipta$489$21,73424 claims
AbbVieLinzess$20$16,86329 claims
AstraZenecaFarxiga$107$10,72312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →